Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549

Medical Oncology

Volumn 28, Issue 2, 2011, Pages 565-571

  Zhu, Fang ^a   Zhang, Zhe ^a   Wu, Gang ^a   Li, Zhenyu ^a   Zhang, Ruiguang ^a   Ren, Jinghua ^a   Nong, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Fasudil; Invasion; Lung cancer; Migration; RhoA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FASUDIL; GELATIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; RHO KINASE; VASCULOTROPIN;

ARTICLE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960300426     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9468-5     Document Type: Article

References (24)

1. RT Greenlee MB Hill-Harmon T Murray M Thun 2001 Cancer statistics CA Cancer J Clin 51 15 36 11577478 10.3322/canjclin.51.1.15 1:STN:280: DC%2BD3MrjtFGisg%3D%3D
2. A Hall 1998 Rho GTPases and the actin cytoskeleton Science 279 509 514 9438836 10.1126/science.279.5350.509 1:CAS:528:DyaK1cXotVKrsQ%3D%3D (Pubitemid 28067271)
3. G Fritz C Brachetti F Bahlmann M Schmidt B Kaina 2002 Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters Br J Cancer 87 635 644 12237774 10.1038/sj.bjc.6600510 1:CAS:528:DC%2BD38XntVGqu7Y%3D
4. T Kamai T Tsujii K Arai K Takagi H Asami, et al. 2003 Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer Clin Cancer Res 9 2632 2641 12855641 1:CAS:528:DC%2BD3sXlt1yrsrc%3D (Pubitemid 36842107)
5. VM Zohrabian B Forzani Z Chau R Murali M Jhanwar-Uniyal 2009 Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation Anticancer Res 29 119 123 19331140 1:CAS:528:DC%2BD1MXjtFGgs7c%3D
6. T Kamai K Arai T Tsujii M Honda K Yoshida 2001 Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour BJU Int 87 227 231 11167647 10.1046/j.1464-410x.2001.02030.x 1:CAS:528: DC%2BD3MXhsVWrtLw%3D (Pubitemid 32142533)
7. HB Wang XP Liu J Liang K Yang AH Sui, et al. 2009 Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters Clin Chem Lab Med 47 811 817 19499974 10.1515/CCLM.2009.186 1:CAS:528:DC%2BD1MXpsFOksb0%3D
8. G Fritz I Just B Kaina 1999 Rho GTPases are overexpressed in human tumors Int J Cancer 81 682 687 10328216 10.1002/(SICI)1097-0215(19990531)81:5<682:: AID-IJC2>3.0.CO;2-B 1:CAS:528:DyaK1MXjtF2kt7o%3D (Pubitemid 29214373)
9. Y Sasaki M Suzuki H Hidaka 2002 The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway Pharmacol Ther 93 225 232 12191614 10.1016/S0163-7258(02)00191-2 1:CAS:528:DC%2BD38XksVShuro%3D (Pubitemid 34615563)
10. X Yang Y Liu Z Zong D Tian 2010 The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells Biomed Pharmacother 64 58 62 19879105 10.1016/j.biopha.2009.08.006 1:CAS:528:DC%2BC3cXnvFeh
11. L Yin K Morishige T Takahashi K Hashimoto S Ogata, et al. 2007 Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo Mol Cancer Ther 6 1517 1525 17513600 10.1158/1535-7163.MCT-06-0689 1:CAS:528:DC%2BD2sXotFaltL8%3D (Pubitemid 46954018)
12. DE Kleiner WG Stetler-Stevenson 1999 Matrix metalloproteinases and metastasis Cancer Chemother Pharmacol 43 Suppl S42 S51 10357558 10.1007/s002800051097 1:CAS:528:DyaK1MXjtlWktbw%3D
13. A Lochter MJ Bissell 1999 An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases APMIS 107 128 136 10190289 10.1111/j.1699-0463.1999.tb01535.x 1:CAS:528: DyaK1MXitFalsL8%3D (Pubitemid 29133532)
14. ML Corcoran RE Hewitt DE Kleiner WG Stetler-Stevenson 1996 MMP-2: expression, activation and inhibition Enzyme Protein 49 7 19 8796994 1:CAS:528:DyaK28XjvVGjtLc%3D (Pubitemid 26181734)
15. K Gohji N Fujimoto I Hara A Fujii A Gotoh, et al. 1998 Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension Int J Cancer 79 96 101 9495366 10.1002/(SICI)1097-0215(19980220)79:1<96::AID-IJC18>3.0.CO;2-F 1:STN:280:DyaK1c7lsVOmtg%3D%3D (Pubitemid 28157734)
16. MA Moses D Wiederschain KR Loughlin D Zurakowski CC Lamb, et al. 1998 Increased incidence of matrix metalloproteinases in urine of cancer patients Cancer Res 58 1395 1399 9537238 1:CAS:528:DyaK1cXit1eksro%3D (Pubitemid 28193598)
17. JE Rundhaug 2005 Matrix metalloproteinases and angiogenesis J Cell Mol Med 9 267 285 15963249 10.1111/j.1582-4934.2005.tb00355.x 1:CAS:528: DC%2BD2sXlvFCluro%3D
18. E Laack A Scheffler I Burkholder I Boeters B Andritzky G Schuch, et al. 2005 Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC) Lung Cancer 50 1 51 58 15992959 10.1016/j.lungcan.2005. 05.011 (Pubitemid 41297469)
19. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 10.1056/NEJM197108122850711 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
20. DW Leung G Cachianes WJ Kuang DV Goeddel N Ferrara 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1306 1309 2479986 10.1126/science.2479986 1:CAS:528:DyaK3cXls1GltLo%3D (Pubitemid 20066716)
21. S Rousseau F Houle J Landry J Huot 1997 p38MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells Oncogene 15 2169 2177 9393975 10.1038/sj.onc.1201380 1:CAS:528:DyaK2sXnsFajsrs%3D (Pubitemid 27493906)
22. G Hashimoto I Inoki Y Fujii T Aoki E Ikeda, et al. 2002 Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165 J Biol Chem 277 36288 36295 12114504 10.1074/jbc.M201674200 1:CAS:528:DC%2BD38XnsVCjtrY%3D
23. E Tachibana T Harada M Shibuya K Saito M Takayasu, et al. 1999 Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage Acta Neurochir (Wien) 141 13 19 10.1007/s007010050260 1:STN:280:DyaK1M7ntFSktw%3D%3D (Pubitemid 29062727)
24. MV Ralph C Bernard K Deborah BS William G Steven, et al. 2005 Efficacy and safety of fasudil in patients with stable angina: a double-bind, placebo-controlled, phase 2 trial J Am Coll Cardiol 46 1803 1811 10.1016/j.jacc.2005.07.047 (Pubitemid 41579800)